Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) announced that its wholly-owned subsidiary, Zhejiang Saimer Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA) for the drug BIOS2242 oral solution, which is aimed at treating cerebral ischemic diseases [1] Group 1: Product Development - The BIOS2242 oral solution is designed to address treatment challenges in conditions such as stroke, cerebral ischemia, and cerebral infarction, which can lead to symptoms like coma, consciousness disorders, paralysis, and limb numbness [1] - Traditional oral solid dosage forms, such as tablets and capsules, are often limited in use due to difficulties in swallowing or oral intake by patients [1] - The oral solution format provides a better medication option, simplifying the administration process and improving the feasibility and accuracy of drug intake [1] Group 2: Market Position - Currently, there are no approved products in the domestic and international markets that are equivalent to BIOS2242 oral solution [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Saimo Pharmaceutical, has received clinical trial approval from the National Medical Products Administration (NMPA) for the drug BIOS2242 oral solution, which is intended for the treatment of mild to moderate acute ischemic stroke [1] Group 1 - The drug BIOS2242 oral solution is specifically designed for treating mild to moderate acute ischemic stroke [1]

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) announced that its wholly-owned subsidiary, Zhejiang Saimer Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA) for the oral solution BIOS2242, which is aimed at treating cerebral ischemic diseases such as stroke and cerebral infarction [1] Group 1 - The approved drug BIOS2242 oral solution addresses the limitations of traditional solid oral dosage forms like tablets and capsules, which are often unsuitable for patients experiencing swallowing difficulties due to symptoms of cerebral ischemic diseases [1] - The oral solution provides a better medication option for patients, simplifying the administration process and improving the feasibility and accuracy of drug intake [1] - Currently, there are no similar products approved for market release domestically or internationally, indicating a potential competitive advantage for the company [1]

证券代码：301096 证券简称：百诚医药 公告编号：2025-059 注册分类：2.2 类 适应症：用于治疗轻、中度急性缺血性脑卒中 申请人：浙江赛默制药有限公司 受理号：CXHL2500895 杭州百诚医药科技股份有限公司 关于全资子公司申报的BIOS2242口服溶液 获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 杭州百诚医药科技股份有限公司（以下简称"公司"）全资子公司浙江赛默制药 有限公司（"赛默制药"）近日收到国家药品监督管理局（NMPA）临床试验批准通知 书，赛默制药申报的药品 BIOS2242 口服溶液获得国家药品监督管理局（NMPA）临床 试验批准通知书。现将情况公告如下： 一、药品基本情况 药品名称：BIOS2242 口服溶液 本次获得临床试验批准，对公司近期业绩不会产生重大影响。后续公司将根据国 家药品注册相关的法律法规规定组织开展临床试验，由于药品研发的特殊性，药品从 临床试验到获准上市的周期长、环节多、风险大、投入高，易受到诸多不可预测的因 素影响，临床试验进度及结果、产品能否获批上市、未来产品市场竞争形 ...

经公司审慎审查，根据《深圳证券交易所创业板股票上市规则》（以下简称"《上 市规则》"）的相关规定，公司与浙江众神创新医药科技有限公司（以下简称"众神 创新"）存在关联关系。众神创新的法定代表人和高级管理人员冯恩光先生为公司原 副总经理，其于 2025 年 2 月 7 日不再担任公司该职务并于 6 月离职。根据《上市规 则》，过去十二个月内担任公司高级管理人员的人员为上市公司关联自然人，因冯恩 光先生目前在众神创新担任高级管理人员，众神创新为公司的关联法人。因此公司与 众神创新的本次交易构成关联交易，此项交易尚需获得公司股东大会的批准。 截至目前，原协议项下的合作尚未实际开展。为严格遵守相关法律法规要求，公 司与众神创新于 2025 年 11 月 14 日签订了《技术开发合作协议》补充协议，将原《技 术开发合作协议》的生效日期修改为自公司股东大会审议通过之日起生效，其他条款 不变。公司将按规定把该合作事项提交董事会及股东大会审议。 公司董事会对于本次合作事项在首次披露时未及时识别关联关系进行深刻检讨， 并向广大投资者致以诚挚的歉意。公司未来将进一步加强在公司治理、信息披露等方 面的工作质量。 证券代码：3010 ...

Market Overview - The medical services sector declined by 0.47% on November 14, with the digital human sector leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Notable declines in individual stocks include: - Digital Human: closed at 17.28, down 4.85% with a trading volume of 80,400 shares and a turnover of 1.411 million [1] - Haoyuan Pharmaceutical: closed at 77.20, down 3.54% with a trading volume of 30,800 shares and a turnover of 2.4212 million [1] - Yinos: closed at 48.69, down 2.62% with a trading volume of 14,300 shares and a turnover of 7132.217 [1] - Other notable declines include Taige Pharmaceutical, MediX, and WuXi AppTec, all showing declines between 1.28% and 2.08% [1] Capital Flow - The medical services sector experienced a net outflow of 238 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [3] - Notable capital flows for specific stocks include: - Ruizhi Pharmaceutical: net inflow of 38.93 million yuan from institutional investors, but net outflows from retail and speculative investors [3] - Chengda Pharmaceutical: net inflow of 37.96 million yuan from institutional investors, with significant outflows from speculative investors [3] - Other stocks like Sanbo Brain Science and Jinyu Medical also showed varying net inflows and outflows among different investor types [3]

Core Viewpoint - Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. has signed a technology development cooperation agreement with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. to advance the BIOS-0629 project, focusing on the treatment of solid tumors in the Greater China region [1][2]. Group 1: Project Overview - The BIOS-0629 project is an in-house developed product by Baicheng Pharmaceutical, targeting solid tumor indications and currently in the PCC (Preclinical Candidate) stage [2]. - The cooperation is limited to the Greater China region, including mainland China and Hong Kong, Macau, and Taiwan, while other rights remain with Baicheng Pharmaceutical [2]. Group 2: Cooperation Details - The agreement specifies clear roles: Baicheng Pharmaceutical will handle research, clinical trials, and registration, while Zhongshen Innovative will manage development, production, sales, and market expansion in the Greater China region [3]. - The total transaction amount is set at 300 million yuan, with milestone payments made by Zhongshen Innovative based on research progress, and Baicheng Pharmaceutical will receive a 10% commission on sales after the product is launched in the Greater China region [3]. Group 3: Counterparty Background - Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. was established on August 5, 2025, with a registered capital of 10.755 million yuan, focusing on medical research and technology development [4]. - The company has a good credit status and strong payment capability, ensuring its ability to fulfill contractual obligations [4]. Group 4: Impact on Company - The signing and implementation of the agreement are expected to positively impact Baicheng Pharmaceutical's future operating performance, enhancing its pipeline in the oncology treatment sector and improving profitability [5]. - The company emphasizes that the contract will not adversely affect its business independence, and it will not become dependent on the counterparty for its main operations [5].

Core Viewpoint - Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. has signed a technology development cooperation agreement with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. to advance the BIOS-0629 project, focusing on the treatment of solid tumors in the Greater China region [1][2]. Group 1: Project Overview - The BIOS-0629 project is an in-house developed product by Baicheng Pharmaceutical, targeting solid tumor indications and currently in the Preclinical Candidate (PCC) stage [2]. - The cooperation is limited to the Greater China region, including mainland China and Hong Kong, Macau, and Taiwan, while other rights remain with Baicheng Pharmaceutical [2]. Group 2: Cooperation Details - The agreement outlines clear responsibilities: Baicheng Pharmaceutical will handle research, clinical trials, and registration, while Zhongshen Innovative will manage development, production, sales, and market expansion in the Greater China region [3]. - The total transaction amount is set at 300 million yuan, with milestone payments made by Zhongshen Innovative based on research progress, along with a 10% sales commission for Baicheng Pharmaceutical upon product launch in the region [3]. Group 3: Counterparty Background - Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. was established on August 5, 2025, with a registered capital of 10.755 million yuan, focusing on medical research and technology development [4]. - The company has a good credit status and strong payment capability, ensuring its ability to fulfill contractual obligations [4]. Group 4: Impact on Company - The agreement is expected to positively impact Baicheng Pharmaceutical's future operating performance, enhancing its pipeline in the oncology treatment sector and improving profitability [5]. - The company emphasizes that the contract will not adversely affect its business independence, as it will not create dependency on the counterparty [5].

智通财经APP讯，百诚医药(301096.SZ)发布公告，公司于近期就自主研发的BIOS-0629项目与浙江众神 创新医药科技有限公司(简称"众神创新")达成合作意向并签署《技术开发合作协议》。 合作方式：公司负责合作产品的研究开发工作、临床试验、注册申报等工作。众神创新负责大中华区域 的研发转化、上市后生产销售和市场拓展工作。交易价格：人民币3亿元。结算方式：合同签署后，众 神创新根据研发节点支付里程碑款3亿元。合作产品大中华区上市后，公司另享有销售额10%的提成收 益。 ...

Core Viewpoint - 百诚医药 has entered into a collaboration agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for the development of the BIOS-0629 project, indicating a strategic partnership aimed at enhancing product development and market reach in the Greater China region [1] Group 1: Collaboration Details - The collaboration involves 百诚医药 being responsible for research and development, clinical trials, and registration applications for the product [1] - 浙江众神创新 will handle R&D transformation, production, sales, and market expansion in the Greater China region [1] Group 2: Financial Terms - The total transaction price for the collaboration is set at RMB 300 million [1] - Payment will be made in milestone payments of RMB 300 million upon reaching specific R&D milestones after the contract is signed [1] - Additionally, 百诚医药 will receive a 10% commission on sales revenue from the product once it is launched in the Greater China market [1]